Macquarie Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Macquarie Group’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,227	Closed	-$13K	–	2415
2020 Q3	$13K	Hold	4,227	–	–	﹤0.01%	2253
2020 Q2	$12K	Buy	+4,227	New	+$13.4K	﹤0.01%	2271
2019 Q1	–	Sell	-2,800	Closed	-$8K	–	2327
2018 Q4	$8K	Sell	2,800 -4,000	-59%	-$11K	﹤0.01%	1980
2018 Q3	$18K	Sell	6,800 -61,440	-90%	-$151K	﹤0.01%	1924
2018 Q2	$160K	Sell	68,240 -231,600	-77%	-$647K	﹤0.01%	1727
2018 Q1	$882K	Buy	299,840 +6,800	+2%	+$18.6K	﹤0.01%	1215
2017 Q4	$803K	Buy	293,040 +41,900	+17%	+$129K	﹤0.01%	1302
2017 Q3	$851K	Buy	+251,140	New	+$698K	﹤0.01%	1268
2013 Q4	–	Sell	-131,764	Closed	-$1.05M	–	1719
2013 Q3	$1.05M	Buy	131,764 +5,312	+4%	+$42.7K	﹤0.01%	1159
2013 Q2	$976K	Buy	+126,452	New	+$986K	﹤0.01%	1161

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

Macquarie Group's PDLI Position: Q4 2020 in Review

Macquarie Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 4,227 shares — an estimated $13K sold.

Macquarie Group first reported a position in PDLI in Q2 2013 and held it in 10 quarters. The position peaked at $1.05M in Q3 2013. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

Macquarie Group reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
Macquarie Group sold 4,227 PDL BioPharma, Inc. shares in Q4 2020, an estimated $13K.
Macquarie Group first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 10 quarters.
Macquarie Group's PDL BioPharma, Inc. position peaked at $1.05M in Q3 2013.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Macquarie Group's 13F filing for Q4 2020, filed 16 Feb 2021.